Last reviewed · How we verify
DF 01
DF 01 is a small molecule drug that targets the mechanism of action of a specific enzyme.
DF 01 is a small molecule drug that targets the mechanism of action of a specific enzyme. Used for Hypertension.
At a glance
| Generic name | DF 01 |
|---|---|
| Also known as | Tafoxiparin |
| Sponsor | Dilafor AB |
| Drug class | small molecule |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of DF 01 is not well understood, but it is believed to inhibit the activity of this enzyme, leading to a decrease in the production of a certain biomarker.
Approved indications
- Hypertension
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors (PHASE3)
- Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest (PHASE2)
- Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01) (NA)
- Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |